Patient Engagement Needs 'Regulatory Guardrails' To Encourage Firms, Advocates Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidance development initiative led by National Health Council and Genetic Alliance will propose to FDA ways to de-risk industry efforts to get patients involved in drug development process.
You may also be interested in...
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Agency reviewers believed the line between patient input and external intimidation had been crossed; early data from the Sarepta muscular dystrophy drug's flawed development program stoked patient community expectations and made regulatory review difficult.
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.